Virupaksha Organics Plans ₹740 Crore IPO, Focus on Expansion and Debt Reduction

Hyderabad, 30 September 2025 – Virupaksha Organics Limited has filed draft papers for an initial public offering of ₹740 crore, only through a fresh issue of shares to be listed on the NSE and the BSE. The offer(s) for sale are not listed in the issue structure. However, the company may proceed with a pre-IPO placement of up to ₹148 crore, which may lower the fresh issue size should it proceed, if it does. The lead managers are Axis Capital & SBI Capital Markets, and KFin Technologies will be the registrar.

Established in 1997 and converted into a public company in 2012, Virupaksha Organics has built a presence in the global pharmaceutical ingredients market, supported by regulatory approvals for its facilities and a diversified client base. The company’s mix of APIs, intermediates, and CDMO services positions it to capture growing demand across domestic and international markets.

Virupaksha Organics IPO Issue Snapshot

The issuance will consist of a fresh issuance of ₹740 crores, with no offer for sale. The issue also provides a pre-IPO placement of up to ₹148 crores. Shares will be listed on the NSE and BSE, with Axis Capital and SBI Capital Markets serving as the book-running lead managers.

Virupaksha Organics IPO Utilization of Proceeds

The proceeds from the IPO will be allocated as follows: ₹360 crore towards expanding manufacturing capacity, ₹195 crore towards repayment or prepayment of borrowings, and the remaining proceeds will be used for general corporate purposes.

Virupaksha Organics IPO Business Overview

Virupaksha Organics is involved in the production of active pharmaceutical ingredients (APIs), intermediates, key starting materials (KSMs), and contract development and manufacturing organization (CDMO) services. Six manufacturing facilities and an R&D centre serve over 550 customers in more than 100 countries.

Its portfolio comprises 54 products, including 23 APIs and 31 intermediates, with a strong focus on therapeutic areas such as analgesics, antihistamines, and antifungals.

Virupaksha Organics IPO Financial Highlights

In FY25, the company reported revenue of ₹811.71 crore and profit of ₹78.71 crore, up from ₹765.99 crore and ₹73.68 crore in FY24. Total borrowings rose to ₹282.23 crore, while net worth increased to ₹456.62 crore.

Virupaksha Organics IPO Strategic Focus

The company intends to strengthen its backward integration, scale up production across Units 1, 2, 4, and 5, and improve cost efficiencies. Investments will be directed toward civil works, new equipment, and utilities to enhance capacity and support future growth.

Virupaksha Organics IPO Key Risks

The business faces concentration in select therapeutic areas, reliance on regulatory clearances across multiple geographies, and compliance challenges linked to environmental permissions. Notices issued by state pollution authorities against two plants have been addressed, with one unit cleared to resume operations and another awaiting re-inspection.

REF: https://www.bseindia.com/corporates/download/371752/IPO Prior/VirupakshaOrganicsLimitedDRHP_20250930104154.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations